High court rejects former InterMune CEO's First Amendment claim

12/23/2013 | Pharmalot

The Supreme Court declined to hear an appeal in the case of former InterMune CEO W. Scott Harkonen, who claimed that information he disseminated about a clinical trial was protected speech under the First Amendment. The FDA said the press release in question contained false and misleading statements.

View Full Article in:

Pharmalot

Published in Brief:

SmartBrief Job Listings for Health Care